Omni makes a round to double its drug insurance
Omni – which created a drug insurance product that is already used by Azul, Light, MetLife and Spoleto – has just closed a round that will finance an aggressive expansion plan: doubling its base of insured lives by the end of next year, reaching revenue of R$ 50 million. The investment was led by ACNext, a venture capital manager founded by former Accenture executives; and had the participation…
Omni, a Brazilian startup, has closed a funding round to support an aggressive expansion plan, aiming to double its user base by the end of next year and reach R$ 50 million in revenue. The funding round was led by ACNext, a venture capital firm founded by former Accenture executives, and included participation from existing investors GreenRock and Enseada.
Omni offers a medication insurance service used by companies such as Azul, Light, MetLife, and Spoleto, and has raised a total of R$ 30 million in three funding rounds since its founding in 2024. The startup aims to reach breakeven by the end of 2027 and has projected revenue of R$ 50 million for that year.
Written by urgent.news from Brazil Journal's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
